Capital Cell

Capital Cell operates as Europe's primary alternative investment platform for the Life Sciences and Biotechnology sector. The company facilitates connections between early-stage biotech and life science companies seeking capital and a diverse pool of investors. It employs a rigorous selection process, leveraging a global network of experts to meticulously vet opportunities, ensuring that only the most promising innovations are presented on its platform.

The firm was established in 2015 within the scientific ecosystem of Barcelona by Daniel Oliver, a biologist who transitioned into entrepreneurship and finance. Oliver founded Capital Cell with the foundational insight of democratizing access to high-impact investments within the biotech sector, thereby enabling a broader range of individuals and entities to contribute to significant advancements in human health.

Capital Cell serves a wide array of clients, including individual private investors, venture capital funds, business angels, family offices, and institutional investors, alongside the innovative biotech companies it funds. Its overarching vision is to globally drive innovation in health and biotechnology, actively shaping a better future by transforming medicine and fostering breakthroughs in human health through strategic investment.